Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin a from Clostridium difficile

Infection and Immunity

Volumn 67, Issue 10, 1999, Pages 5124-5132

  Ward, Stephen J ^a,b   Douce, Gill ^b   Dougan, Gordon ^b   Wren, Brendan W ^a,c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; RECOMBINANT PROTEIN; TETANUS TOXIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HEMAGGLUTINATION; IMMUNIZATION; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

EID: 0032829877     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.10.5124-5132.1999     Document Type: Article

References (54)

1. Barroso, L. A., S. Z. Wang, C. J. Phelps, J. L. Johnson, and T. D. Wilkins. 1990. Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res. 18:4004.
2. Cartmill, T. D. I., H. Panigrahi, M. A. Worsley, D. C. McCann, C. N. Nice, and E. Keith. 1994. Management and control of a large outbreak of diarrhoea due to Clostridium difficile. J. Hosp. Infect. 27:1-15.
3. Chabalgoity, J. A., C. M. Khan, A. A. Nash, and C. E. Hormaeche. 1996. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol. Microbiol. 19:791-801.
4. Chatfield, S. N., N. Fairweather, I. Charles, D. Pickard, M. Levine, D. Hone, M. Posada, R. A. Strugnell, and G. Dougan. 1992. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine 10:53-60.
5. Christodoulides, M., B. T. McGuiness, and J. E. Heckels. 1993. Immunisation with synthetic peptides containing epitopes of the class 1 outer membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunisation with a cyclic peptide. J. Gen. Microbiol. 139:1729-1738.
6. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
7. Critchley, D. R., W. H. Habig, and P. H. Fishman. 1986. Reevaluation of the role of gangliosides as receptors for tetanus toxin. J. Neurochem. 47:213-222.
8. Cropley, I., G. Douce, M. Roberts, S. Chatfield, M. Pizza, I. Marsili, R. Rappuoli, and G. Dougan. 1995. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment. Vaccine 13:1643-1648.
9. Dillon, S. T., E. J. Rubin, M. Yakubovich, C. Pothoulakis, J. T. LaMont, L. A. Feig, and R. J. Gilbert. 1995. Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect. Immun. 63:1421-1426.
10. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:2821-2828.
11. Douce, G., M. M. Giuliani, V. Giannelli, M. Pizza, R. Rappuoli, and G. Dougan. 1998. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16:1065-1073.
12. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644-1648.
13. Dove, C. H., S. Z. Wang, S. B. Price, C. J. Phelps, D. M. Lyerly, T. D. Wilkins, and J. L. Johnson. 1990. Molecular characterization of the Clostridium difficile toxin A gene. Infect. Immun. 58:480-488.
14. Fairweather, N. F., V. A. Lyness, and D. J. Maskell. 1987. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect. Immun. 55:2541-2545.
15. Fekety, R., J. Silva, C. Kauffman, B. Buggy, H. Gunner, and H. Deery. 1989. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am. J. Med. 86:15-19.
16. George, R. H., J. M. Symonds, F. Dimock, J. D. Brown, Y. Arabi, N. Shinagawa, M. R. B. Keighley, J. Alexander Williams, and D. W. Burdon. 1978. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br. Med. J. 1:695.
17. Giannasca, P. J., J. A. Boden, and T. P. Monath. 1997. Targeted delivery of antigen to hamster nasal lymphoid tissue with M cell-directed lectins. Infect. Immun. 65:4288-4298.
18. Giannasca, P. J., Z.-X. Zhang, W.-D. Lei, J. A. Boden, M. A. Giel, T. P. Monath, and J. W. D. Thomas. 1999. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67:527-538.
19. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1-10.
20. Heard, S. R., S. O'Farrell, D. Holland, S. Crook, M. J. Barnett, and S. Tabaqchali. 1986. The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients. J. Infect. Dis. 153:159-162.
21. Hopkins, S., J. P. Kraehenbuhl, F. Schodel, A. Potts, D. Peterson, P. De Grandi, and D. Nardelli-Haefliger. 1995. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63:3279-3286.
22. Johnson, S., W. D. Sypura, D. N. Gerding, S. L. Ewing, and E. N. Janoff. 1995. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun. 63:3166-3173.
23. Just, I., J. Selzer, M. Wilm, C. von Eichel-Streiber, M. Mann, and K. Aktories. 1995. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375:500-503.
24. Katoh, T., M. Higaki, T. Honda, and T. Miwatani. 1986. Cytotonic effect of Clostridium difficile enterotoxin on Chinese hamster ovary cells. FEMS Microbiol. Lett. 34:241-244.
25. Kelly, C. P., C. Pothoulakis, J. Orellana, and J. T. LaMont. 1992. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 102:35-40.
26. Ketley, J. M., T. J. Mitchell, D. C. Candy, D. W. Burdon, and J. Stephen. 1987. The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits. J. Med. Microbiol. 24: 41-52.
27. Khan, C. M., B. Villarreal-Ramos, R. J. Pierce, G. Riveau, R. Demarco de Hormaeche, H. McNeill, T. Ali, N. Fairweather, S. Chatfield, A. Capron, G. Dougan, and C. E. Hormaeche. 1994. Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. Proc. Natl. Acad. Sci. USA 91:11261-11265.
28. Krivan, H. C., G. F. Clark, D. F. Smith, and T. D. Wilkins. 1986. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gala1-3Galβ1-4GlcNAc. Infect. Immun. 53: 573-581.
29. Krivan, H. C., and T. D. Wilkins. 1987. Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect. Immun. 55:1873-1877.
30. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
31. Larson, H. E., and S. P. Borriello. 1990. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob. Agents Chemother. 34:1348-1353.
32. Larson, H. E., A. B. Price, P. Honour, and S. P. Borriello. 1978. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1:1063-1066.
33. Lyerly, D. M., J. L. Johnson, S. M. Frey, and T. D. Wilkins. 1990. Vaccination against lethal Clostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin A. Curr. Microbiol. 21:29-32.
34. Lyerly, D. M., H. C. Krivan, and T. D. Wilkins. 1988. Clostridium difficile: its disease and toxins. Clin. Microbiol. Rev. 1:1-18.
35. Lyerly, D. M., K. E. Saum, D. K. MacDonald, and T. D. Wilkins. 1985. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47:349-352.
36. McGhee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and H. Kiyono. 1992. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75-88.
37. Mitchell, T. J., J. M. Ketley, D. W. Burdon, D. C. Candy, and J. Stephen. 1987. The effects of Clostridium difficile crude toxins and purified toxin A on stripped rabbit ileal mucosa in Ussing chambers. J. Med. Microbiol. 23:199-204.
38. Moellering, R. C. J. 1998. Vancomycin-resistant enterococci. Clin. Infect. Dis. 26:1196-1199.
39. Pierce, P. F., R. Wilson, and J. Silva. 1982. Antibiotic-associated pseudomembranous colitis: an epidemic investigation of a cluster of cases. J. Infect. Dis. 145:269-274.
40. Price, S. B., C. J. Phelps, T. D. Wilkins, and J. L. Johnson. 1987. Cloning of the carbohydrate-binding portion of the toxin A gene of Clostridium difficile. Curr. Microbiol. 16:82-86.
41. Simor, A. E., S. L. Yake, and K. Tsimidis. 1993. Infection due to Clostridium difficile among elderly residents of a long-term care facility. Clin. Infect. Dis. 17:672-678.
42. Smith, J. A., D. L. Cooke, S. Hyde, S. P. Borriello, and R. G. Long. 1997. Clostridium difficile toxin A binding to human intestinal epithelial cells. J. Med. Microbiol. 44:953-958.
43. Spangler, B. D. 1992. Structure and function of cholera toxin and related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622-647.
44. Staats, H. F., R. J. Jackson, M. Marinaro, I. Takahashi, H. Kiyono, and J. R. McGhee. 1994. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immunol. 6:572-583.
45. Torres, J. F., D. M. Lyerly, J. E. Hill, and T. P. Monath. 1995. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:4619-4627.
46. Tucker, K. D., P. E. Carrig, and T. D. Wilkins. 1990. Toxin A of Clostridium difficile is a potent cytotoxin. J. Clin. Microbiol. 28:869-871.
47. Turner, S. J., F. R. Carbone, and R. A. Strugnell. 1993. Salmonella typhimurium aroA aroD mutants expressing a foreign recombinant protein induce specific major histocompatibility complex class I-restricted cytotoxic T lymphocytes in mice. Infect. Immun. 61:5374-5380.
48. Ward, S. J., G. Douce, D. Figueiredo, G. Dougan, and B. W. Wren. 1999. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect. Immun. 67:2145-2152.
49. Ward, S. J., D. Scopes, M. Christodoulides, I. N. Clarke, and J. E. Heckels. 1996. Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response. Microb. Pathog. 21:499-512.
50. Warny, M., J. P. Vaerman, V. Avesani, and M. Delmee. 1994. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 62:384-389.
51. Wilcox, M. H. 1998. Treatment of Clostridium difficile infection. J. Antimicrob. Chemother. 41:41-46.
52. Wilcox, M. H., and R. C. Spencer. 1992. Clostridium difficile infection: responses, relapses and re-infections. J. Hosp. Infect. 22:85-92.
53. Wren, B. W., R. R. Russell, and S. Tabaqchali. 1991. Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide. Infect. Immun. 59:3151-3155.
54. Wren, B. W., and S. Tabaqchali. 1987. Restriction endonuclease DNA analysis of Clostridium difficile. J. Clin. Microbiol. 25:2402-2404.